Paricalcitol , 95% , 131918-61-1

Synonym(s):
(1α, 3β, 7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol

CAS NO.：131918-61-1

Empirical Formula: C27H44O3

Molecular Weight: 416.65

MDL number:

EINECS: 658-064-6

PRODUCT Properties

• Boiling point: 564.8±50.0 °C(Predicted)
• Density: 1.121±0.06 g/cm3(Predicted)
• Flash point: 14℃
• storage temp.: Store at -20°C,unstable in solution, ready to use.
• solubility: DMSO : 100 mg/mL (240.02 mM; Need ultrasonic)Ethanol : 12.5 mg/mL (30.00 mM; Need ultrasonic)H2O : < 0.1 mg/mL (insoluble)
• pka: 14.34±0.40(Predicted)
• form: Solid
• color: White to off-white
• InChIKey: BPKAHTKRCLCHEA-UBFJEZKGSA-N
• SMILES: C[C@]12CCC/C(=C\C=C3C[C@@H](O)C[C@H](O)C3)/[C@]1([H])CC[C@]2([H])[C@H](C)/C=C/[C@H](C)C(O)(C)C |&1:1,10,13,16,20,22,26,r|
• CAS DataBase Reference: 131918-61-1(CAS DataBase Reference)

Description and Uses

Paricalcitol was launched as Zemplar in the US for the prevention and treatment of secondary hyperthyroidism associated with chronic renal failure. Paricalcitol is a synthetic vitamin D2, namely a novel 1-alpha-hydroxy-19-noranalogue in which the ring A exocyclic methylene group, typical of all vitamin D systems, has been replaced by two hydrogen atoms. Paricalcitol is the first vitamin D analogue marketed for this indication. In patients with chronic renal failure, Paricalcitol appreciably reduced levels of parathyroid hormone (PTH) without a significant difference in the incidence rate for hypercalcemia or hyperphosphatemia when compared with placebo.

Antihyperparathyriod

Safety

• Symbol(GHS): GHS06,GHS08
• Signal word: Danger
• Hazard statements: H301+H311-H330-H372
• Precautionary statements: P280-P301+P310+P330-P302+P352+P312-P304+P340+P310-P314
• RIDADR: UN1170 - class 3 - PG 2 - Ethanol, solution
• HS Code: 2936299055
• Hazardous Substances Data: 131918-61-1(Hazardous Substances Data)